244 related articles for article (PubMed ID: 12902862)
1. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Crane CH; Mason K; Janjan NA; Milas L
Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Rich TA; Shepard R
Am J Clin Oncol; 2003 Aug; 26(4):S110-3. PubMed ID: 12902867
[TBL] [Abstract][Full Text] [Related]
3. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Liao Z; Milas L; Komaki R; Stevens C; Cox JD
Am J Clin Oncol; 2003 Aug; 26(4):S85-91. PubMed ID: 12902863
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors.
Nakata E; Mason KA; Hunter N; Husain A; Raju U; Liao Z; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):369-75. PubMed ID: 14751505
[TBL] [Abstract][Full Text] [Related]
6. [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Hada M; Mizutari K
Gan To Kagaku Ryoho; 2004 Jun; 31(6):959-61. PubMed ID: 15222121
[TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibition and lung cancer.
Sandler AB; Dubinett SM
Semin Oncol; 2004 Apr; 31(2 Suppl 7):45-52. PubMed ID: 15179623
[TBL] [Abstract][Full Text] [Related]
8. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
[TBL] [Abstract][Full Text] [Related]
10. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Cascinu S; Scartozzi M; Carbonari G; Pierantoni C; Verdecchia L; Mariani C; Squadroni M; Antognoli S; Silva RR; Giampieri R; Berardi R
Am J Clin Oncol; 2007 Oct; 30(5):526-30. PubMed ID: 17921715
[TBL] [Abstract][Full Text] [Related]
11. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Milas L; Mason KA; Crane CH; Liao Z; Masferrer J
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):15-24. PubMed ID: 12800601
[TBL] [Abstract][Full Text] [Related]
12. COX-2-Selective NSAIDs: new and improved?
Lichtenstein DR; Wolfe MM
JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
[No Abstract] [Full Text] [Related]
13. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Raut CP; Nawrocki S; Lashinger LM; Davis DW; Khanbolooki S; Xiong H; Ellis LM; McConkey DJ
Cancer Biol Ther; 2004 Dec; 3(12):1217-24. PubMed ID: 15477758
[TBL] [Abstract][Full Text] [Related]
14. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
Choy H; Milas L
J Natl Cancer Inst; 2003 Oct; 95(19):1440-52. PubMed ID: 14519750
[TBL] [Abstract][Full Text] [Related]
15. COX-2 inhibition and colorectal cancer.
Koehne CH; Dubois RN
Semin Oncol; 2004 Apr; 31(2 Suppl 7):12-21. PubMed ID: 15252926
[TBL] [Abstract][Full Text] [Related]
16. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Davis TW; O'Neal JM; Pagel MD; Zweifel BS; Mehta PP; Heuvelman DM; Masferrer JL
Cancer Res; 2004 Jan; 64(1):279-85. PubMed ID: 14729635
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
[TBL] [Abstract][Full Text] [Related]
18. Coming: a review of second-generation nonsteroidal anti-inflammatory drugs.
Housholder GT; Chan JT
J Gt Houst Dent Soc; 1997 Mar; 68(8):13-6. PubMed ID: 9594801
[No Abstract] [Full Text] [Related]
19. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
El-Rayes BF; Ali S; Sarkar FH; Philip PA
Mol Cancer Ther; 2004 Nov; 3(11):1421-6. PubMed ID: 15542781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
